{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T06:57:59Z","timestamp":1790233079360,"version":"4.1.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2017,2,28]],"date-time":"2017-02-28T00:00:00Z","timestamp":1488240000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100002803","name":"Fondazione Cariplo","doi-asserted-by":"publisher","award":["2013-0692"],"award-info":[{"award-number":["2013-0692"]}],"id":[{"id":"10.13039\/501100002803","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharm Res"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1007\/s11095-017-2132-4","type":"journal-article","created":{"date-parts":[[2017,3,1]],"date-time":"2017-03-01T00:43:27Z","timestamp":1488329007000},"page":"1180-1186","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["High Penetration of Paclitaxel in Abdominal Wall of Rabbits after Hyperthermic Intraperitoneal Administration of Nab-Paclitaxel Compared to Standard Paclitaxel Formulation"],"prefix":"10.1007","volume":"34","author":[{"given":"Federico","family":"Coccolini","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Acocella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1301-720X","authenticated-orcid":false,"given":"Lavinia","family":"Morosi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Brizzola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Ghiringhelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Ceresoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrico","family":"Davoli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Ansaloni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maurizio","family":"D\u2019Incalci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Massimo","family":"Zucchetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,2,28]]},"reference":[{"issue":"1","key":"2132_CR1","first-page":"12","volume":"40","author":"F Coccolini","year":"2014","unstructured":"Coccolini F, Cotte E, Glehen O, Lotti M, Poiasina E, Catena F, et al. Intraperitoneal chemotherapy in advanced gastric cancer. Meta-analysis of randomized trials. Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol. 2014;40(1):12\u201326.","journal-title":"Eur J Surg Oncol J Eur Soc Surg Oncol Br Assoc Surg Oncol"},{"issue":"41","key":"2132_CR2","doi-asserted-by":"publisher","first-page":"6979","DOI":"10.3748\/wjg.v19.i41.6979","volume":"19","author":"F Coccolini","year":"2013","unstructured":"Coccolini F, Gheza F, Lotti M, Virz\u00ec S, Iusco D, Ghermandi C, et al. Peritoneal carcinomatosis. World J Gastroenterol. 2013;19(41):6979\u201394.","journal-title":"World J Gastroenterol"},{"issue":"1","key":"2132_CR3","first-page":"29","volume":"7","author":"PH Sugarbaker","year":"2016","unstructured":"Sugarbaker PH, Van der Speeten K. Surgical technology and pharmacology of hyperthermic perioperative chemotherapy. J Gastrointest Oncol. 2016;7(1):29\u201344.","journal-title":"J Gastrointest Oncol"},{"issue":"2","key":"2132_CR4","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1038\/bjc.2014.602","volume":"112","author":"L Ansaloni","year":"2015","unstructured":"Ansaloni L, Coccolini F, Morosi L, Ballerini A, Ceresoli M, Grosso G, et al. Pharmacokinetics of concomitant cisplatin and paclitaxel administered by hyperthermic intraperitoneal chemotherapy to patients with peritoneal carcinomatosis from epithelial ovarian cancer. Br J Cancer. 2015;112(2):306\u201312.","journal-title":"Br J Cancer"},{"issue":"4","key":"2132_CR5","doi-asserted-by":"publisher","first-page":"1183","DOI":"10.1245\/s10434-007-9792-y","volume":"15","author":"E Bree de","year":"2008","unstructured":"de Bree E, Rosing H, Filis D, Romanos J, Melisssourgaki M, Daskalakis M, et al. Cytoreductive surgery and intraoperative hyperthermic intraperitoneal chemotherapy with paclitaxel: a clinical and pharmacokinetic study. Ann Surg Oncol. 2008;15(4):1183\u201392.","journal-title":"Ann Surg Oncol"},{"issue":"12","key":"2132_CR6","doi-asserted-by":"publisher","first-page":"2209","DOI":"10.1007\/s00595-014-0848-x","volume":"44","author":"S Emoto","year":"2014","unstructured":"Emoto S, Sunami E, Yamaguchi H, Ishihara S, Kitayama J, Watanabe T. Drug development for intraperitoneal chemotherapy against peritoneal carcinomatosis from gastrointestinal cancer. Surg Today. 2014;44(12):2209\u201320.","journal-title":"Surg Today"},{"issue":"1","key":"2132_CR7","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.jss.2008.06.049","volume":"155","author":"D Soma","year":"2009","unstructured":"Soma D, Kitayama J, Ishigami H, Kaisaki S, Nagawa H. Different tissue distribution of paclitaxel with intravenous and intraperitoneal administration. J Surg Res. 2009;155(1):142\u20136.","journal-title":"J Surg Res"},{"issue":"5","key":"2132_CR8","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1016\/S1470-2045(03)01074-X","volume":"4","author":"M Markman","year":"2003","unstructured":"Markman M. Intraperitoneal antineoplastic drug delivery: rationale and results. Lancet Oncol. 2003;4(5):277\u201383.","journal-title":"Lancet Oncol"},{"issue":"4","key":"2132_CR9","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1158\/1535-7163.MCT-15-0713-T","volume":"15","author":"L Sim\u00f3n-Gracia","year":"2016","unstructured":"Sim\u00f3n-Gracia L, Hunt H, Scodeller PD, Gaitzsch J, Braun GB, Willmore A-MA, et al. Paclitaxel-loaded Polymersomes for enhanced intraperitoneal chemotherapy. Mol Cancer Ther. 2016;15(4):670\u20139.","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"2132_CR10","doi-asserted-by":"publisher","first-page":"54","DOI":"10.3802\/jgo.2015.26.1.54","volume":"26","author":"F Coccolini","year":"2015","unstructured":"Coccolini F, Campanati L, Catena F, Ceni V, Ceresoli M, Jimenez Cruz J, et al. Hyperthermic intraperitoneal chemotherapy with cisplatin and paclitaxel in advanced ovarian cancer: a multicenter prospective observational study. J Gynecol Oncol. 2015;26(1):54\u201361.","journal-title":"J Gynecol Oncol"},{"issue":"Suppl 1","key":"2132_CR11","first-page":"S40","volume":"20","author":"E Bree de","year":"2015","unstructured":"de Bree E. Optimal drugs for HIPEC in different tumors. J BUON Off J Balk Union Oncol. 2015;20(Suppl 1):S40\u20136.","journal-title":"J BUON Off J Balk Union Oncol"},{"issue":"3","key":"2132_CR12","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.critrevonc.2015.04.004","volume":"95","author":"HJ Braam","year":"2015","unstructured":"Braam HJ, Schellens JH, Boot H, van Sandick JW, Knibbe CA, Boerma D, et al. Selection of chemotherapy for hyperthermic intraperitoneal use in gastric cancer. Crit Rev Oncol Hematol. 2015;95(3):282\u201396.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"2","key":"2132_CR13","doi-asserted-by":"crossref","first-page":"769","DOI":"10.3892\/ol.2014.2764","volume":"9","author":"L-L Liu","year":"2015","unstructured":"Liu L-L, Yi T, Zhao X. Antitumor effect of D-erythrose in an abdominal metastatic model of colon carcinoma. Oncol Lett. 2015;9(2):769\u201373.","journal-title":"Oncol Lett"},{"issue":"1","key":"2132_CR14","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.ijpharm.2014.12.025","volume":"479","author":"AM Mehta","year":"2015","unstructured":"Mehta AM, Van den Hoven JM, Rosing H, Hillebrand MJX, Nuijen B, Huitema ADR, et al. Stability of oxaliplatin in chloride-containing carrier solutions used in hyperthermic intraperitoneal chemotherapy. Int J Pharm. 2015;479(1):23\u20137.","journal-title":"Int J Pharm"},{"key":"2132_CR15","doi-asserted-by":"publisher","first-page":"3767","DOI":"10.2147\/DDDT.S88023","volume":"9","author":"MN Kundranda","year":"2015","unstructured":"Kundranda MN, Niu J. Albumin-bound paclitaxel in solid tumors: clinical development and future directions. Drug Design, Development and Therapy. 2015;9:3767\u201377.","journal-title":"Drug Design, Development and Therapy"},{"issue":"3","key":"2132_CR16","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1016\/j.jconrel.2013.05.041","volume":"170","author":"DA Yardley","year":"2013","unstructured":"Yardley DA. nab-Paclitaxel mechanisms of action and delivery. J Control Release Off J Control Release Soc. 2013;170(3):365\u201372.","journal-title":"J Control Release Off J Control Release Soc"},{"issue":"1","key":"2132_CR17","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1007\/s10856-015-5618-9","volume":"27","author":"X Yu","year":"2016","unstructured":"Yu X, Jin C. Application of albumin-based nanoparticles in the management of cancer. J Mater Sci Mater Med. 2016;27(1):4.","journal-title":"J Mater Sci Mater Med"},{"issue":"11","key":"2132_CR18","doi-asserted-by":"publisher","first-page":"1555","DOI":"10.1038\/sj.bjc.6605642","volume":"102","author":"P Workman","year":"2010","unstructured":"Workman P, Aboagye EO, Balkwill F, Balmain A, Bruder G, Chaplin DJ, et al. Guidelines for the welfare and use of animals in cancer research. Br J Cancer. 2010;102(11):1555\u201377.","journal-title":"Br J Cancer"},{"issue":"5","key":"2132_CR19","doi-asserted-by":"publisher","first-page":"807","DOI":"10.1016\/j.coph.2013.06.003","volume":"13","author":"L Morosi","year":"2013","unstructured":"Morosi L, Zucchetti M, D\u2019Incalci M, Davoli E. Imaging mass spectrometry: challenges in visualization of drug distribution in solid tumors. Curr Opin Pharmacol. 2013;13(5):807\u201312.","journal-title":"Curr Opin Pharmacol"},{"issue":"8","key":"2132_CR20","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0072532","volume":"8","author":"L Morosi","year":"2013","unstructured":"Morosi L, Spinelli P, Zucchetti M, Pretto F, Carr\u00e0 A, D\u2019Incalci M, et al. Determination of paclitaxel distribution in solid tumors by nano-particle assisted laser desorption ionization mass spectrometry imaging. PloS One. 2013;8(8):e72532.","journal-title":"PloS One"},{"issue":"3","key":"2132_CR21","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s00280-005-0160-y","volume":"58","author":"R Fruscio","year":"2006","unstructured":"Fruscio R, Lissoni AA, Frapolli R, Corso S, Mangioni C, D\u2019Incalci M, et al. Clindamycin-paclitaxel pharmacokinetic interaction in ovarian cancer patients. Cancer Chemother Pharmacol. 2006;58(3):319\u201325.","journal-title":"Cancer Chemother Pharmacol"},{"issue":"11","key":"2132_CR22","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1593\/neo.09866","volume":"11","author":"M Cesca","year":"2009","unstructured":"Cesca M, Frapolli R, Berndt A, Scarlato V, Richter P, Kosmehl H, et al. The effects of vandetanib on paclitaxel tumor distribution and antitumor activity in a xenograft model of human ovarian carcinoma. Neoplasia N Y N. 2009;11(11):1155\u201364.","journal-title":"Neoplasia N Y N"},{"issue":"7","key":"2132_CR23","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1007\/s11095-011-0401-1","volume":"28","author":"W Bouquet","year":"2011","unstructured":"Bouquet W, Deleye S, Staelens S, De Smet L, Van Damme N, Debergh I, et al. Antitumour efficacy of two paclitaxel formulations for hyperthermic intraperitoneal chemotherapy (HIPEC) in an in vivo rat model. Pharm Res. 2011;28(7):1653\u201360.","journal-title":"Pharm Res"},{"issue":"6","key":"2132_CR24","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1007\/BF00685656","volume":"34","author":"JL Eiseman","year":"1994","unstructured":"Eiseman JL, Eddington ND, Leslie J, MacAuley C, Sentz DL, Zuhowski M, et al. Plasma pharmacokinetics and tissue distribution of paclitaxel in CD2F1 mice. Cancer Chemotherapy and Pharmacology. 1994;34(6):465\u201371.","journal-title":"Cancer Chemotherapy and Pharmacology"},{"issue":"1","key":"2132_CR25","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1021\/acs.molpharmaceut.5b00383","volume":"13","author":"C Colombo","year":"2016","unstructured":"Colombo C, Morosi L, Bello E, Ferrari R, Licandro SA, Lupi M, et al. PEGylated Nanoparticles Obtained through Emulsion Polymerization as Paclitaxel Carriers. Mol Pharm. 2016;13(1):40\u20136.","journal-title":"Mol Pharm"},{"issue":"2","key":"2132_CR26","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1002\/bmc.3005","volume":"28","author":"Y Wei","year":"2014","unstructured":"Wei Y, Xue Z, Ye Y, Wang P, Huang Y, Zhao L. Pharmacokinetic and tissue distribution of paclitaxel in rabbits assayed by LC-UV after intravenous administration of its novel liposomal formulation. Biomed Chromatogr BMC. 2014;28(2):204\u201312.","journal-title":"Biomed Chromatogr BMC"},{"issue":"5","key":"2132_CR27","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1097\/IGC.0b013e31824d836c","volume":"22","author":"L Ansaloni","year":"2012","unstructured":"Ansaloni L, Agnoletti V, Amadori A, Catena F, Cavaliere D, Coccolini F, et al. Evaluation of extensive cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in patients with advanced epithelial ovarian cancer. Int J Gynecol Cancer Off J Int Gynecol Cancer Soc. 2012;22(5):778\u201385.","journal-title":"Int J Gynecol Cancer Off J Int Gynecol Cancer Soc"},{"key":"2132_CR28","doi-asserted-by":"publisher","unstructured":"Mu\u00f1oz-Casares FC, Rufi\u00e1n S, Arjona-S\u00e1nchez \u00c1, Rubio MJ, D\u00edaz R, Casado \u00c1, et al. Neoadjuvant intraperitoneal chemotherapy with paclitaxel for the radical surgical treatment of peritoneal carcinomatosis in ovarian cancer: a prospective pilot study. Cancer Chemother Pharmacol. 2011;68(1):267\u201374.","DOI":"10.1007\/s00280-011-1646-4"},{"issue":"11","key":"2132_CR29","first-page":"753","volume":"11","author":"FC Mu\u00f1oz-Casares","year":"2009","unstructured":"Mu\u00f1oz-Casares FC, Rufi\u00e1n S, Rubio MJ, D\u00edaz CJ, D\u00edaz R, Casado A, et al. The role of hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) in the treatment of peritoneal carcinomatosis in recurrent ovarian cancer. Clin Transl Oncol Off Publ Fed Span Oncol Soc Natl Cancer Inst Mex. 2009;11(11):753\u20139.","journal-title":"Clin Transl Oncol Off Publ Fed Span Oncol Soc Natl Cancer Inst Mex"},{"issue":"2","key":"2132_CR30","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/jso.21448","volume":"101","author":"JH Kim","year":"2010","unstructured":"Kim JH, Lee JM, Ryu KS, Lee YS, Park YG, Hur SY, et al. Consolidation hyperthermic intraperitoneal chemotherapy using paclitaxel in patients with epithelial ovarian cancer. J Surg Oncol. 2010;101(2):149\u201355.","journal-title":"J Surg Oncol"},{"issue":"1","key":"2132_CR31","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1016\/j.ygyno.2007.03.019","volume":"106","author":"JH Bae","year":"2007","unstructured":"Bae JH, Lee JM, Ryu KS, Lee YS, Park YG, Hur SY, et al. Treatment of ovarian cancer with paclitaxel- or carboplatin-based intraperitoneal hyperthermic chemotherapy during secondary surgery. Gynecol Oncol. 2007;106(1):193\u2013200.","journal-title":"Gynecol Oncol"},{"issue":"4","key":"2132_CR32","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1002\/jso.20597","volume":"94","author":"S Rufi\u00e1n","year":"2006","unstructured":"Rufi\u00e1n S, Mu\u00f1oz-Casares FC, Brice\u00f1o J, D\u00edaz CJ, Rubio MJ, Ortega R, et al. Radical surgery-peritonectomy and intraoperative intraperitoneal chemotherapy for the treatment of peritoneal carcinomatosis in recurrent or primary ovarian cancer. J Surg Oncol. 2006;94(4):316\u201324.","journal-title":"J Surg Oncol"},{"issue":"3C","key":"2132_CR33","first-page":"3019","volume":"23","author":"E Bree de","year":"2003","unstructured":"de Bree E, Romanos J, Michalakis J, Relakis K, Georgoulias V, Melissas J, et al. Intraoperative hyperthermic intraperitoneal chemotherapy with docetaxel as second-line treatment for peritoneal carcinomatosis of gynaecological origin. Anticancer Res. 2003;23(3C):3019\u201327.","journal-title":"Anticancer Res"},{"issue":"2","key":"2132_CR34","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1097\/00001813-200302000-00003","volume":"14","author":"E Bree de","year":"2003","unstructured":"de Bree E, Rosing H, Beijnen JH, Romanos J, Michalakis J, Georgoulias V, et al. Pharmacokinetic study of docetaxel in intraoperative hyperthermic i.P. Chemotherapy for ovarian cancer. Anticancer Drugs. 2003;14(2):103\u201310.","journal-title":"Anticancer Drugs"},{"issue":"1","key":"2132_CR35","doi-asserted-by":"crossref","first-page":"89","DOI":"10.3892\/or.2014.3210","volume":"32","author":"J Kinoshita","year":"2014","unstructured":"Kinoshita J, Fushida S, Tsukada T, Oyama K, Watanabe T, Shoji M, et al. Comparative study of the antitumor activity of Nab-paclitaxel and intraperitoneal solvent-based paclitaxel regarding peritoneal metastasis in gastric cancer. Oncol Rep. 2014;32(1):89\u201396.","journal-title":"Oncol Rep"},{"issue":"9","key":"2132_CR36","first-page":"2486","volume":"47","author":"PH Wiernik","year":"1987","unstructured":"Wiernik PH, Schwartz EL, Strauman JJ, Dutcher JP, Lipton RB, Paietta E. Phase I clinical and pharmacokinetic study of taxol. Cancer Res. 1987;47(9):2486\u201393.","journal-title":"Cancer Res"},{"issue":"4","key":"2132_CR37","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1007\/s00280-015-2833-5","volume":"76","author":"N Chen","year":"2015","unstructured":"Chen N, Brachmann C, Liu X, Pierce DW, Dey J, Kerwin WS, et al. Albumin-bound nanoparticle (nab) paclitaxel exhibits enhanced paclitaxel tissue distribution and tumor penetration. Cancer Chemother Pharmacol. 2015;76(4):699\u2013712.","journal-title":"Cancer Chemother Pharmacol"},{"key":"2132_CR38","doi-asserted-by":"publisher","unstructured":"Mielke S, Sparreboom A, Mross K. Peripheral neuropathy: a persisting challenge in paclitaxel-based regimes. Eur J Cancer Oxf Engl 1990. 2006;42(1):24\u201330.","DOI":"10.1016\/j.ejca.2005.06.030"},{"issue":"4","key":"2132_CR39","first-page":"1237","volume":"8","author":"H Gelderblom","year":"2002","unstructured":"Gelderblom H, Verweij J, van Zomeren DM, Buijs D, Ouwens L, Nooter K, et al. Influence of Cremophor el on the bioavailability of intraperitoneal paclitaxel. Clin Cancer Res Off J Am Assoc Cancer Res. 2002;8(4):1237\u201341.","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"5","key":"2132_CR40","doi-asserted-by":"publisher","first-page":"1274","DOI":"10.1038\/ki.1995.182","volume":"47","author":"L Gotloib","year":"1995","unstructured":"Gotloib L, Shostak A. Endocytosis and transcytosis of albumin gold through mice peritoneal mesothelium. Kidney Int. 1995;47(5):1274\u201384.","journal-title":"Kidney Int"},{"key":"2132_CR41","doi-asserted-by":"publisher","first-page":"32180","DOI":"10.1038\/srep32180","volume":"6","author":"D Shang","year":"2016","unstructured":"Shang D, Peng T, Gou S, Li Y, Wu H, Wang C, et al. High Mobility Group Box Protein 1 Boosts Endothelial Albumin Transcytosis through the RAGE\/Src\/Caveolin-1 Pathway. Sci Rep. 2016;6:32180.","journal-title":"Sci Rep"},{"issue":"11","key":"2132_CR42","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1369\/jhc.4A6334.2004","volume":"52","author":"CJ Ruhland von","year":"2004","unstructured":"von Ruhland CJ, Campbell L, Gumbleton M, Jasani B, Newman GR. Immunolocalization of caveolin-1 in rat and human mesothelium. J Histochem Cytochem Off J Histochem Soc. 2004;52(11):1415\u201325.","journal-title":"J Histochem Cytochem Off J Histochem Soc"}],"container-title":["Pharmaceutical Research"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11095-017-2132-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-017-2132-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11095-017-2132-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,3]],"date-time":"2020-10-03T06:30:29Z","timestamp":1601706629000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11095-017-2132-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,2,28]]},"references-count":42,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["2132"],"URL":"https:\/\/doi.org\/10.1007\/s11095-017-2132-4","relation":{},"ISSN":["0724-8741","1573-904X"],"issn-type":[{"value":"0724-8741","type":"print"},{"value":"1573-904X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,2,28]]}}}